Back to search
IgA Monoclonal Gammopathy of Undetermined Significance
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IgA Monoclonal Gammopathy of Undetermined Significance trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which IgA Monoclonal Gammopathy of Undetermined Significance trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifa…
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpo…
This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the in…
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease. Open to indivi…